Emerging drugs for chronic constipation.
Chronic constipation (CC) is one of the most common functional gastrointestinal disorders. CC is estimated to affect up to 27% of the North American population. Although not life-threatening, CC can have profoundly negatively affects on quality of life and result in significant economic burden in terms of both direct and indirect healthcare costs. Possible etiologies for CC include alterations in gastrointestinal motility and secretion. Research efforts in CC have begun to identify multifactorial and often overlapping etiologies including abnormalities in myenteric neurons, alterations in neurotransmitters and their receptors, and incoordination of the muscles of the pelvic floor or anorectum. CC may be influenced by genetic predisposition, environmental factors and stress. In this article, the safety and efficacy of traditional and emerging therapies for CC are examined.
Crowell
Michael D
MD
Mayo Clinic, Mayo Clinic College of Medicine, Division of Gastroenterology, Scottsdale, 13400 East Shea Blvd, Scottsdale, AZ 85259, USA. Crowell.Michael@mayo.edu
Harris
Lucinda A
LA
Lunsford
Tisha N
TN
Dibaise
John K
JK
D000701:Analgesics, Opioid / Q000009:adverse effects; D002400:Cathartics / Q000627:therapeutic use*; D065101:Chloride Channel Agonists; D002908:Chronic Disease; D003248:Constipation / Q000139:chemically induced / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D055808:Drug Discovery; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D009037:Motilin / Q000819:agonists; D009292:Narcotic Antagonists / Q000627:therapeutic use; D045265:Natriuretic Peptides / Q000819:agonists; D018490:Serotonin Agents / Q000627:therapeutic use
D000701:Analgesics, Opioid; D002400:Cathartics; D065101:Chloride Channel Agonists; D009292:Narcotic Antagonists; D045265:Natriuretic Peptides; D018490:Serotonin Agents; C084362:uroguanylin; D009037:Motilin